Free weekly newsletter

Get the free weekly executive digest

The new leadership moves, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New leadership moves, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Leadership Trends

See who's moving and how much in your market

No credit card required Weekly executive digest

Takeda Names Julie Kim As Successor To Representative Director President CEO Christophe Weber

PUBLIC · TAKJan 30, 2025•over 1 year ago

Position

Director

Company

Takeda Pharmaceutical Company

Julie Kim

Tokyopharmaceuticals

Description

Takeda Pharmaceutical Company Limited has announced the unanimous decision of its board of directors to appoint Julie Kim, the current U.S. Business Unit President, as the successor to Christophe Weber, who will retire as Representative Director President CEO in June 2026.

Company Information

Company

Takeda Pharmaceutical Company

Location

Tokyo, Tokyo, Japan

About

Takeda Pharmaceutical Company is a global, research and development-driven pharmaceutical company. It focuses on bringing innovative medicines to patients in areas of unmet medical need. The company operates in a wide range of therapeutic areas, including oncology, gastroenterology, and rare diseases.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for Takeda Pharmaceutical Company's next move

Learn about Strategic plan

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months